Catalent Launches ADVASEPT Advanced Aseptic Technology
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, will launch its new ADVASEPT technology, for the advanced aseptic filling of injectable drugs, at the forthcoming INTERPHEX exhibition, which takes place 18–20 March at the Javits Center, New York City, NY.
The new platform provides a glass-free, aseptically filled, primary container that reduces or eliminates many concerns associated with traditional glass vials, including the risk of injuries to treatment providers and patients, the potential for glass particulate contamination and accidental breakage in transit and subsequent product wastage.
“This new technology eliminates the risk of glass particulate contamination, significantly reduces the risk of breakages and minimizes container weight through the use of an ultrapure plastic design,” commented Catalent’s Jonathan Arnold, Vice President and General Manager of Advanced Delivery Technologies. “Catalent also brings analytical expertise in areas such as biologic substance testing, extractables and leachables, and stability, and we have scientifically shown comparability of a monoclonal antibody between traditional glass and ADVASEPT vials.”
ADVASEPT vial production leverages proven Quality by Design manufacturing techniques that have optimised the blow-fill-seal manufacturing process. Leveraging this form of advanced aseptic processing, a stopper is inserted during the blow-fill-seal process to create a next generation, glass-free injectable solution, minimizing the risk of contamination by reducing particles, process steps, and human interaction. Significant reductions in controlled space requirements also drive out the operational and fixed costs of traditional vial filling while decreasing the risk of contamination.
Available with safe, easy to open pop-off or twist-off tops, the ADVASEPT stoppered vial is currently produced in 10 mL, 50 mL and 100 mL sizes. ADVASEPT vials are manufactured at Catalent’s Woodstock, IL facility, and are highly customizable. Containers can be tailored to meet the unique needs of customers across many markets, such as biologics, pharmaceuticals, generics, and animal health.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.